AbbVie Psoriatic Arthritis Drug Shows Long-term Effect On Skin, Joint Symptoms

  • AbbVie Inc ABBV announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials of Skyrizi (risankizumab) in active psoriatic arthritis. 
  • Results showed that at week 100 of the open-label extension period, patients receiving SKYRIZI reported improvement in skin and joint symptoms, with more than half of patients in KEEPsAKE 1 and 2 achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90). 
  • Additionally, the data demonstrated no new observed safety signals through 100 weeks.
  • At week 100, pooled results showed that 76% and 57% of patients, respectively, initially treated with Skyrizi, achieved resolution of dactylitis and enthesitis.
  • Skyriszi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
  • Price Action: ABBV shares are up 0.85% at $142.62 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!